查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586227

子宫颈癌诊断市场：按类型、最终用户划分 - 全球预测 2025-2030

Cervical Cancer Diagnostic Market by Type (Cervical Biopsies, Colposcopy, Cystoscopy), End-User (Cancer & Radiation Therapy Centers, Hospital, Speciality Clinics & Diagnostic Centers) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年子宫颈癌诊断市场价值为201.4亿美元，预计到2024年将达到221.5亿美元，复合年增长率为10.03%，到2030年将达到393.5亿美元。

子宫颈癌诊断市场包括旨在检测和诊断子宫颈癌的各种工具和技术。该系列包括子宫颈抹片、HPV 检测、切片检查和先进的成像工具，为早期诊断提供了多方面的方法，这对于实现有效的治疗结果至关重要。这些诊断的需求源于透过早期检测降低子宫颈癌死亡率的需要以及 HPV 感染的全球盛行率。应用主要集中在进行常规医疗检查的妇女诊所、医院和诊断实验室，重点是旨在加强患者护理和管理的医疗服务的最终用途。市场成长受到人们对子宫颈癌认识不断提高、政府推动子宫颈癌筛检计画的倡议以及诊断工具技术进步等因素的显着影响。潜在的机会包括扩大新兴市场的筛检计划以及整合人工智慧和机器学习以提高诊断准确性和效率。创新者可以透过开发新型诊断分析和可携式测试设备来获得资金，以满足资源匮乏环境和远端医疗应用的需求。儘管潜力巨大，但该市场仍面临挑战，例如先进诊断程序的高成本、农村地区获得医疗保健的机会有限以及影响产品核可时间表的监管障碍。透过政策建议和对负担得起的诊断技术的投资来解决这些限制将推动市场成长。研究和开发工作应着重于个人化医疗方法和非侵入性诊断的开发，以提高患者的依从性。市场充满活力且竞争激烈，驾驭复杂性并抓住机会需要持续创新和策略伙伴关係。

主要市场统计
基准年[2023] 201.4亿美元
预测年份 [2024] 221.5亿美元
预测年份 [2030] 393.5亿美元
复合年增长率（%） 10.03%

市场动态：快速发展的子宫颈癌诊断市场的关键市场洞察

供需的动态交互作用正在改变子宫颈癌诊断市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 子宫颈癌患者增加
    • 非侵入性手术越来越受欢迎和倾向
    • 政府扩大医疗基础设施的倡议
  • 市场限制因素
    • 与诊断程序相关的高成本
  • 市场机会
    • 癌症诊断设备的发展和技术进步
    • 管道诊断工具继续核准监管机构批准
  • 市场挑战
    • 严格且耗时的法规环境

波特五力：驾驭子宫颈癌诊断市场的策略工具

波特的「五力」框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对子宫颈癌诊断市场的影响

外部宏观环境因素在塑造子宫颈癌诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解子宫颈癌诊断市场的竞争状况

子宫颈癌诊断市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵子宫颈癌诊断市场供应商的绩效评估

FPNV 定位矩阵是评估子宫颈癌诊断市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了子宫颈癌诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对子宫颈癌诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 子宫颈癌发生率增加
      • 非侵入性手术的日益普及和趋势
      • 政府努力扩大医疗基础设施
    • 抑制因素
      • 与诊断程序相关的高成本
    • 机会
      • 癌症诊断设备的发展与技术进步
      • 管道诊断工具继续核准监管机构批准
    • 任务
      • 耗时且严格的法规环境
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章子宫颈癌诊断市场：依类型

  • 子宫颈切片检查
  • 阴道镜检查
  • 膀胱镜检查
  • HPV检测
  • 子宫颈抹片检查

第七章子宫颈癌诊断市场：依最终用户分类

  • 癌症与放射治疗中心
  • 医院
  • 专科诊所和诊断中心

第八章北美和南美子宫颈癌诊断市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区子宫颈癌诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲子宫颈癌诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Advaxis Inc.
  • Arbor Vita Corporation
  • Beckman Coulter Inc. by Danaher Corporation
  • Becton, Dickinson and Company
  • Bio Farma
  • Bristol-Myers Squibb Company
  • Cardinal Health, Inc.
  • CooperSurgical, Inc.
  • Dr Lal PathLabs Pvt. Ltd.
  • DYSIS Medical Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hologic, Inc.
  • Merck & Co. Inc.
  • MobileODT
  • oncgnostics GmbH
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Zilico Ltd.
Product Code: MRR-4756B70362E8

The Cervical Cancer Diagnostic Market was valued at USD 20.14 billion in 2023, expected to reach USD 22.15 billion in 2024, and is projected to grow at a CAGR of 10.03%, to USD 39.35 billion by 2030.

The cervical cancer diagnostic market encompasses a range of tools and techniques aimed at detecting and diagnosing cervical cancer. This scope includes Pap smears, HPV testing, biopsies, and advanced imaging tools, which together provide a multi-faceted approach to early diagnosis, critical for effective treatment outcomes. The necessity for these diagnostics stems from the need to reduce cervical cancer mortality rates through early detection and the growing prevalence of HPV infections globally. Applications are primarily focused on women's health clinics, hospitals, and diagnostic laboratories where routine screenings are conducted, emphasizing the end-use scope in healthcare services that aim to enhance patient care and management. Market growth is significantly influenced by factors such as increasing awareness of cervical cancer, government initiatives promoting cervical screening programs, and technological advancements in diagnostic tools. Potential opportunities include the expansion of screening programs in emerging markets and the integration of AI and machine learning to improve diagnostic accuracy and efficiency. Innovators can capitalize by developing novel diagnostic assays and portable testing devices to meet the needs of low-resource settings and telemedicine applications. Despite its potential, the market faces challenges such as high costs of advanced diagnostic procedures, limited access to healthcare in rural areas, and regulatory hurdles affecting product approval timelines. Addressing these limitations through policy advocacy and investment in affordable diagnostic technologies can foster market growth. R&D efforts should focus on personalized medicine approaches and developing non-invasive diagnostic methods to enhance patient compliance. The market is dynamic and competitive, requiring continuous innovation and strategic partnerships to navigate its complexities and seize opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 20.14 billion
Estimated Year [2024] USD 22.15 billion
Forecast Year [2030] USD 39.35 billion
CAGR (%) 10.03%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cervical Cancer Diagnostic Market

The Cervical Cancer Diagnostic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cervical cancer cases
    • Rising popularity and inclination towards non-invasive procedures
    • Government initiatives to expand healthcare infrastructure
  • Market Restraints
    • High cost associated with diagnostic procedures
  • Market Opportunities
    • Development and technological advancements in cancer diagnostic devices
    • Ongoing approvals from regulatory agencies of pipeline diagnostic tools
  • Market Challenges
    • Time-consuming and stringent regulatory environment

Porter's Five Forces: A Strategic Tool for Navigating the Cervical Cancer Diagnostic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cervical Cancer Diagnostic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cervical Cancer Diagnostic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cervical Cancer Diagnostic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cervical Cancer Diagnostic Market

A detailed market share analysis in the Cervical Cancer Diagnostic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cervical Cancer Diagnostic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cervical Cancer Diagnostic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cervical Cancer Diagnostic Market

A strategic analysis of the Cervical Cancer Diagnostic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cervical Cancer Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Advaxis Inc., Arbor Vita Corporation, Beckman Coulter Inc. by Danaher Corporation, Becton, Dickinson and Company, Bio Farma, Bristol-Myers Squibb Company, Cardinal Health, Inc., CooperSurgical, Inc., Dr Lal PathLabs Pvt. Ltd., DYSIS Medical Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hologic, Inc., Merck & Co. Inc., MobileODT, oncgnostics GmbH, Qiagen NV, Quest Diagnostics Incorporated, Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Zilico Ltd..

Market Segmentation & Coverage

This research report categorizes the Cervical Cancer Diagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cervical Biopsies, Colposcopy, Cystoscopy, HPV Testing, and Pap Smear Test.
  • Based on End-User, market is studied across Cancer & Radiation Therapy Centers, Hospital, and Speciality Clinics & Diagnostic Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cervical cancer cases
      • 5.1.1.2. Rising popularity and inclination towards non-invasive procedures
      • 5.1.1.3. Government initiatives to expand healthcare infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with diagnostic procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Development and technological advancements in cancer diagnostic devices
      • 5.1.3.2. Ongoing approvals from regulatory agencies of pipeline diagnostic tools
    • 5.1.4. Challenges
      • 5.1.4.1. Time-consuming and stringent regulatory environment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cervical Cancer Diagnostic Market, by Type

  • 6.1. Introduction
  • 6.2. Cervical Biopsies
  • 6.3. Colposcopy
  • 6.4. Cystoscopy
  • 6.5. HPV Testing
  • 6.6. Pap Smear Test

7. Cervical Cancer Diagnostic Market, by End-User

  • 7.1. Introduction
  • 7.2. Cancer & Radiation Therapy Centers
  • 7.3. Hospital
  • 7.4. Speciality Clinics & Diagnostic Centers

8. Americas Cervical Cancer Diagnostic Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cervical Cancer Diagnostic Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cervical Cancer Diagnostic Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Advaxis Inc.
  • 3. Arbor Vita Corporation
  • 4. Beckman Coulter Inc. by Danaher Corporation
  • 5. Becton, Dickinson and Company
  • 6. Bio Farma
  • 7. Bristol-Myers Squibb Company
  • 8. Cardinal Health, Inc.
  • 9. CooperSurgical, Inc.
  • 10. Dr Lal PathLabs Pvt. Ltd.
  • 11. DYSIS Medical Inc.
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. GlaxoSmithKline PLC
  • 14. Hologic, Inc.
  • 15. Merck & Co. Inc.
  • 16. MobileODT
  • 17. oncgnostics GmbH
  • 18. Qiagen NV
  • 19. Quest Diagnostics Incorporated
  • 20. Siemens Healthineers AG
  • 21. Thermo Fisher Scientific Inc.
  • 22. Zilico Ltd.

LIST OF FIGURES

  • FIGURE 1. CERVICAL CANCER DIAGNOSTIC MARKET RESEARCH PROCESS
  • FIGURE 2. CERVICAL CANCER DIAGNOSTIC MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CERVICAL CANCER DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CERVICAL CANCER DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CERVICAL CANCER DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CERVICAL CANCER DIAGNOSTIC MARKET DYNAMICS
  • TABLE 7. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY CERVICAL BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COLPOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY CYSTOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY HPV TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY PAP SMEAR TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY CANCER & RADIATION THERAPY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY SPECIALITY CLINICS & DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM CERVICAL CANCER DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. CERVICAL CANCER DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. CERVICAL CANCER DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023